medigraphic.com
ISSN 0185-6014 (Impreso)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2003, Número 4

<< Anterior Siguiente >>

Rev Mex Patol Clin Med Lab 2003; 50 (4)


Hepatitis C.
Historia natural y estado actual de su manejo

Terrés-Speziale AM

Idioma: Español
Referencias bibliográficas: 53
Paginas: 179-189
Archivo PDF: 262.61 Kb.


RESUMEN

A poco más de diez años de su descubrimiento en 1989 y de su ubicación con respecto a la hepatitis no-A no-B, en México existen relativamente pocos artículos que evalúen la historia natural del virus de la hepatitis C (VHC) en las que se incluyan: virología, epidemiología, factores de riesgo, clínica y autoinmunidad, detección de anti-VHC, aminotransferasas, detección del virus, pronóstico, tratamiento y precauciones universales. A pesar de que esta enfermedad es una causa mayor de hepatopatía crónica en el ámbito mundial, tenemos que reconocer que nuestro conocimiento es actualmente limitado aun cuando se trata de un problema de gran importancia médica. El virus de la hepatitis C se caracteriza por ser hepatotrópico y linfotrópico por lo que, además de ser causa de hepatitis crónica, cirrosis y hepatocarcinoma, también es una causa importante de enfermedades autoinmunes y dermatosis diversas. Existen patrones epidemiológicos distintivos en cada región, así como cofactores y manifestaciones extrahepáticas que dificultan la comprensión y el manejo de este padecimiento. Mucha de la información actualmente disponible es el resultado de estudios retrospectivos de casos publicados en revistas internacionales.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Choo Ql, Kuo G, Wiener Aj et al. Isolation of CDNA clone derived from blood-borne non–A, non-B viral hepatitis genome. Science 1989; 244: 359-361.

  2. Kuo G, Choo Ql, Alter Hj et al. An assay for circulating antibodies to a major etiologic virus human non-A, non-B hepatitis. Science 1989; 244: 362-364

  3. S Mehta, H L Bonkovsky. Hepatitis C: A review and update. J Am Acad Dermatol 2001; 44 (2): 159-182.

  4. Hepatitis C Infection: A Review. Lippincott’s Primary Care Practice [Computer File], 1999; (3): 345-353.

  5. Conte SVP. Chronic viral hepatitis C. Part 1. General considerations. Arch Gastroenterol 2000; 37 (3): 187-194.

  6. Alberti A, Chemello A et al. Natural history of hepatitis C. J Hepatology 1999; 31 (suppl 1): 17-24.

  7. Pagliaro L, Peri V, Linea C et al. Natural history of chronic hepatitis C. Source digestive and liver disease. Intern J Gastroenterol Hepatol 1999; 31 (1): 28-44.

  8. Palafox-Zaldivar A. Hepatitis por virus C. Bol Med Hosp Infant Mex 1999; 56 (9): 520-531.

  9. Halabe-Cherem J. Hepatitis. Rev Fac Med UNAM 2000; 43 (3).

  10. Choo Ql, Weiner Aj, Overby Lr, Kuo G, Houghton M. Hepatitis C virus: The major causative agent of viral non-A, non-B hepatitis. Br Med Bul 1990; 46: 423-441

  11. Sánchez GF; Terrés SAM. Frecuencia de anticuerpos anti-VHC. Anales Médicos 1991; 3: 94.

  12. Zarate MFE. Prevalencia de Ac contra el VHC en personal médico del INP. Acta Pediatr Mex 1995: 16 (1): 6-8.

  13. Flores CMS. Seropositividad de la infección por VHC y HBV en estudiantes universitarios en el Edo de NL, Mex. Rev Gastroenterol Mex 1996; 61 (4): 327-331.

  14. Ayala GJJ. Prevalencia de marcadores virales para hepatitis B,C y HIV en donadores de sangre voluntarios del NE de México. Rev Gastroenterol Mex 1997; 62 (4): 250-253.

  15. Merle V, Goria O, Gourier-Frery C, Benguigui C, Huet P. Risk factors of contamination by hepatitis C virus. Case-control study in the general population. Gastroenterologie Clinique Et Biologique 1999; 23 (4): 439-446.

  16. Trevisan A, Bicciato F, Fanelli G, Stocco E, Paruzzolo P. Risk of hepatitis C virus infection in a population exposed to biological materials. Am J Indust Med 1999; 35 (5): 532-535.

  17. Kumar Rachana M. Interspousal and intrafamilial transmission of hepatitis C virus: A myth or a concern? Obstetr Gynecol 1998; 91 (3): 426-431.

  18. Resti M, Azzari C, Mannelli F, Moriondo M, Novembre E, De Martino M, Vierucci A. Mother to child transmission of hepatitis C virus: Prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. Br Med J 1998; 317 (7156): 437-441.

  19. Pianko S, Patella S, Sievert W. Alcohol consumption induces hepatocyte apoptosis in patients with chronic hepatitis C infection. J Gastroenterol Hepatol 2000; 15 (7): 798-806.

  20. Rambusch EG, Manns MP. Extrahepatic manifestations of hepatitis C infection. Zeitschrift Fur Gastroenterologie 1998; 36 (7): 579-586.

  21. Alvarado EC. Inmunologia de la hepatitis C. Rev Invest Clin 1999; 51 (5): 315-322.

  22. Kristiansen MG, Florholmen J. Extrahepatic manifestations in hepatitis C. Are they overlooked? Tidsskrift For Den Norske Lageforening: Tidsskrift For Praktisk Medicin, Ny Rakke 2001; 121 (4): 446-449.

  23. Ouzan D, Pesle B, Baldini E, Rimbourg H et al. Epidemiological information obtained from anti-hepatitis C virus screening in blood donors and candidates for autologous transfusion from 1992 to 1996 in the Alpes-Maritimes Region. Gastroenterologie Clinique et Biologique 2000; 24 (3): 337-341.

  24. Soldan K, Barbara JA, Heptonstall J. Incidence of seroconversion to positivity for hepatitis C antibody in repeat blood donors in England, 1993-5. Br Med J 1998; 316 (7142): 1413-1417.

  25. Gordon FD. Cost-effectiveness of screening patients for hepatitis C. Am J Med 1999; 107 (6b): 36s-40s.

  26. Brunton C, Kemp R, Raynel P, Harte D, Baker M. Cumulative incidence of hepatitis C seroconversion in a cohort of seronegative injecting drug users. Med Assoc New Zealand 2000; 113 (1106): 98-100.

  27. Montagnese F, Castellacci R, Puoti C. Hepatitis C Virus carriers with persistently normal aminotransferase levels: Healthy people or true patients? Dig Liver Dis: Inter J Gastroenterol Hepatol 2001; 32 (7): 634-643.

  28. Busch MP, Korelitz JJ, Kleinman SH, Lee SR et al. Declining value of alanine aminotransferase in screening blood donors to prevent postransfusion hepatitis B and C virus infection. J Hepatol 1995; 23: 742-745.

  29. Kleinman S, Alter H, Busch MP, Holland P, Tegtmeier G, Nelles M et al. Increased detection of hepatitis C virus (HCV) infected blood donors by a multiple antigen HCV enzyme immunoassay. Transfusion 1992; 32: 805-813.

  30. Nakatsuji Y, Matsumoto A, Tanaka E, Ogata H, Kiyosawa K. Detection of chronic hepatitis C virus infection by four diagnostic systems: 1st and 2nd generation ELISA, 2nd gen recombinant immunoblot assay and Nested Pcr. Hepatology 1992; 16: 300-305.

  31. Tanaka T, Lau Jy, Mizokami M, Orito E et al. Simple fluorescent eia for detection and quantification of hepatitis C viremia. J Hepatol 1995; 23 (6): 742-745.

  32. Orito E, Mizokami M, Tanaka T et al. Quantification of serum hepatitis C virus core protein level in patients chronically infected with different hepatitis C virus genotypes. Gut 1996; 39: 876-880.

  33. Negro F, Giostra E, Krawczynski K, Quadri R, Rubbia-Brandt L, Mentha G et al. Detection of intrahepatic hepatitis C virus replication by strand-specific semi-quantitative Rt-PCR: Preliminary application to the liver transplantation model. J Hepatol 1998; 29 (1): 1-11.

  34. Robbins DJ, Pasupuleti V, Cuan J, Chiang CS. Reverse Transcriptase PCR quantitation of hepatitis C virus. Clin Laborat Sci 2000; 13 (1): 23-30.

  35. Peterson J, Green G, Lida K, Caldwell B, Kerrison P, Bernich S et al. Detection of hepatitis C core antigen in the antibody negative “window” phase of hepatitis B infection. Vox Sang 2000; 78: 80-85.

  36. Tanaka E, Chiharu O, Katsumi A et al. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology 2000; 32 (2) 388-393.

  37. Bird SM, Goldberg DJ, Hutchinson SJ. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data. J Epidemiol Biostat 2001; 6 (3): 243-265.

  38. Bird SM, Goldberg DJ, Hutchinson SJ. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 2: Preliminary UK estimates of prevalent injection-related hepatitis C carriers, and derivation of progression rates to liver cirrhosis by gender and age at hepatitis C virus infection. J Epidemiol Biostat 2001; 6 (3): 267-277.

  39. Babany G, Bourlière M, Chevalier H, Desmorat H, Gournay J, Loiseau D et al. Do general practitioners want to manage chronic hepatitis C and take part in hepatitis C health networks? A national survey. Gastroenterologie Clinique Et Biologique 1999; 23 (12): 1289-1295.

  40. Shehab S et al. Management of hepatitis C patients by primary care physicians in the USA: Results of a national survey. J Viral Hepatitis 2001; 8 (5): 377-383.

  41. Schwinger W, Deutsch J, Benesch M, Kerbl R, Preisegger KH, Lackner H et al. Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics 2000; 106 (4): E53.

  42. Hoofnagle JH. Management of hepatitis C: Current and future perspectives. J Hepatol 1999; 31 (suppl 1): 264-268.

  43. Centers For Disease Control. Update: Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR 1988; 37 (24); 377-387.

  44. National Committee for Clinical Laboratory Standards. Protection of laboratory workers from instrument biohazards and infectious disease transmitted by blood, body fluids and tissue; Approved guideline. Villanova, PA: National Committee For Clinical Laboratory Standards, 1997;7 (9). (Nccls Document M29-P).

  45. Occupational Exposure to Hazardous Chemicals in Laboratories, 29 Cfr 1910.1450.

  46. Occupational Exposure To Bloodborne Pathogens, 29 Cfr 1910.1030.

  47. World Health Organization, Laboratory biosafety manual. 2nd ed. 1993.

  48. Technical manual. 12th Ed. Washington, DC: American Association of Blood Banks. US Dhhs Biosafety in Microbiological and Biomedical Laboratories. 1996.

  49. Sehulster LM, Hollinger FB, Dreesman GR, Melnick JL. Immunological and biophysical alteration of hepatitis B virus antigens by sodium hypochlorite disinfection. Appl Environ Microbiol 1981; 42: 762-767.

  50. Bond WW, Favero MS, Peterson NJ, Ebert JW. Inactivation of hepatitis B virus by intermediate-to-high-level disinfectant chemicals. J Clin Microbiol 1983; 18: 535-538.

  51. Block SS. Disinfection, sterilization and preservation. 4th ed. Philadelphia, PA: Lea and Febiger, 1991.

  52. Council Directive of 7 June 1998 on the Approximation of the Laws, Regulations and Administrative Provisions of the Member Status Relating to the Classification, Packaging and Labeling of Dangerous Preparations (88/379/Eec).

  53. National Committee for Clinical Laboratory Standards. Preparation and testing of reagent water in the clinical laboratory. 2nd ed; Approved Guideline. Villanova, PA: National Committee for Clinical Laboratory Standards, (Nccls Document C3-A2) (Isbn1-562328-127-X). 1991; 11 (13).




2020     |     www.medigraphic.com